Of the 15 participants, three patients developed side effects possibly related to rifabutin during the observational period; two of Group I developed skin rash and the other of Group II developed grade 2 rise in liver enzymes (ALT or AST 2.6–5.0 times of ULN). This evidence concerns the gene GPT and exanthem.